PKD1

Across TCGA pan-cancer cohorts, PKD1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PKD1 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PKD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PKD1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, LUAD, and ESCA are the cancer types where PKD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	OS	Median	II,III,IV	0.210	0.719	<.001	39	view →
ESCA	OS	Median	II,III,IV	0.109	0.931	<.001	30	view →
KIRP	OS	Median	All	0.608	0.903	.005	15	view →
SCLC	OS	Median	II,III,IV	0.189	0.579	.027	3	view →
COAD	DFS	Median	IV	0.176	0.502	.017	3	view →
SKCM	DFS	Median	II,III,IV	0.843	0.657	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PKD1–THYM (OS)

Open the THYM breakdown →